Search clinical trials for: ASP6858

Total 5 results

Astellas Pharma Europe B.V.

Completed

A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects

Healthy Volunteers

United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses

Healthy Subjects | Pharmacokinetics of ASP4058 | Food Effect of ASP4058

United States
Novartis Pharmaceuticals

Completed

Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)

Depression

United States
Astellas Pharma Inc
Astellas Pharma Global Development, Inc.

Completed

An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Solid Tumors

United States, Japan, Korea, Republic of, Taiwan
Astellas Pharma Global Development, Inc.

Terminated

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

Non-hematologic Malignancies | Pharmacokinetics of ASP9853

United States

3

Subscribe